Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis
Infliximab, an anti-TNF-alpha monoclonal antibody, is an effective treatment for ulcerative colitis (UC) with over 60% of patients responding to treatment and up to 30% reaching remission. The mechanism of resistance to anti-TNF-alpha is unknown. This study used colonic mucosal gene expression to provide a predictive response signature for infliximab treatment in UC.
Provenance — who produced it, who reused it
Linked to 16 papers in the literature. Roles are inferred factual signals (who deposited the data vs who reused it), with counts — never a judgement about any author.
- Intra- and Inter-cellular Rewiring of the Human Colon during Ulc... 2019 · 1,445 cites
- COX-2–PGE2 Signaling Impairs Intestinal Epithelial Regeneration... 2018 · 107 cites
- Quantification of biological network perturbations for mechanist... 2014 · 104 cites
13 further papers cite this accession but reuse could not be confirmed.
Deep data QC
metadata only · no data-level QC for this typeStandardized, field-standard QC computed by touching the data — every metric states how it was obtained
No quantitative QC rubric exists for this data type yet, so it is deliberately left unscored — this is an honest "not applicable", not a poor rating.
measured = computed from the data · extrapolated/reported = derived or from the repository · dq-1.0 · provisional — verify independently